Screener
Beta Bionics BBNX Accounts Receivable, Credit Loss Expense (Reversal)
Accounts Receivable, Credit Loss Expense (Reversal) at other companies
Other financials
Where this comes from
Reported directly by Beta Bionics in its filing.
Tagged under the XBRL concept us-gaap:ProvisionForDoubtfulAccounts.
The source filing: Beta Bionics’s 10-K, filed February 24, 2026.
- Filed
- Feb 24, 2026, 4:20 PM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-067065
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 |
|---|---|---|
| Net loss | $(73,200) | $(54,756) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 1,573 | 1,151 |
| Provision for expected credit losses | 40 | 70 |
| Stock-based compensation expense | 16,384 | 6,384 |
| Net provision for excess and obsolete inventory | 1,478 | (636) |
| Change in fair value of warrant liabilities | 12,450 | 13,412 |
| Accretion of discount on short-term investments | (2,054) | (2,905) |
Item 14. Principal Accounting Fees and Services.
FAQ
- What is Beta Bionics's accounts receivable, credit loss expense (reversal)?
- Beta Bionics (BBNX) reported accounts receivable, credit loss expense (reversal) of $16K in Q4 2025.
- How has Beta Bionics's accounts receivable, credit loss expense (reversal) changed year-over-year?
- Beta Bionics's accounts receivable, credit loss expense (reversal) decreased by 38.5% year-over-year, from $26K to $16K.
- What is the long-term trend for Beta Bionics's accounts receivable, credit loss expense (reversal)?
- Over 2 years (2023 to 2025), Beta Bionics's accounts receivable, credit loss expense (reversal) has grown at a -6.7% compound annual growth rate (CAGR), from $46K to $40K.
Ask your AI about Beta Bionics's accounts receivable, credit loss expense (reversal).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude